Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EBT Medical

Explore full profile

EBT Medical is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders

Toronto, CanadaFounded 2014Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2019
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for EBT Medical and the history behind them.

About EBT Medical

EBT Medical, a clinical-stage company founded in 2014, is focused on developing neuromodulation technologies to address pelvic health disorders. The company originated from scientific discoveries at the University of Toronto. The founders are Professor Paul Yoo, who serves as President and Chief Scientific Officer, and Dr. Sasha John, the Chief Innovation Officer. Professor Yoo's research background is in neuromodulation for conditions including lower urinary function, while Dr. John is an entrepreneur and inventor with extensive experience in neurostimulation and data assessment. Keith R. Carlton, an executive with over 20 years in the medical device field, including roles at Medtronic and Boston Scientific, leads the company as CEO.

Read full description

The company's business model centers on creating and commercializing non-invasive medical devices for a market that currently relies on pharmaceutical or more invasive therapies. EBT Medical has secured $10 million in a Series A funding round, co-led by SV Health Investors and Genesys Capital, to advance its technology and pursue clinical data for safety and effectiveness. The firm's primary product under development is the NiNA™ (Noninvasive Neuromodulation Assistant) system, designed to treat overactive bladder (OAB). This system utilizes a proprietary and patented approach targeting the Saphenous nerve.

The NiNA™ device is a wearable neurostimulator placed on the patient's upper calf for daily 30-minute sessions. It operates through noninvasive Saphenous Neuromodulation (nSAFN) therapy. The system includes the NiNA Care™ mobile application for both iOS and Android, which connects to the device via Bluetooth. This app allows patients to control their therapy sessions and provides a platform for data collection to support ongoing clinical trials. The entire ecosystem is designed to offer a discreet treatment alternative without the side effects associated with traditional OAB therapies. As a clinical-stage company, the NiNA system is currently in development and has not yet received market authorization for sale.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Toronto, Canada
Employees
11
Open positions
None listed
Dealroom signal
65.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning EBT Medical.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Nov 2019 $10M $40M SV Health Investors · Genesys Capital
GRANTOther financing Oct 2018 $100K MassChallenge
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

EBT Medical website traffic

Latest recorded traffic for EBT Medical is 1.8K monthly website visits, up 93.5% over the last three months. EBT Medical's team declined 8.3% over the past year.

Latest monthly visits1.8K 3-month web change+93.5% 1-year team growth-8.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada (NSERC)
  • BioEnterprise
  • AGE-WELL
  • Ontario Bioscience Industry Organization
  • MassChallenge

Series A2 investors entered at this stage

  • SV Health Investors
  • Genesys Capital

Other known investors2 additional known investors

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇦 Canada55.6%
🇺🇸 United States33.3%
🇮🇳 India11.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EBT Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EBT Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.